Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy

Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01327170

Enrollment

Registered

2011-04-01

Start date

2008-11-30

Completion date

2010-06-30

Last updated

2011-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy

Brief summary

The aim of this study was to evaluate safety and therapeutic response to micropulse diode 810nm laser treatment in patients with chronic central serous chorioretinopathy.

Detailed description

Most of the cases of central serous chorioretinopathy (CSC) recur spontaneously within three months of disease. After 3 months without resolution of acute CSC or in chronic CSC, continuous wave laser photocoagulation or photodynamic therapy should be considered. Direct threshold continuous photocoagulation treatment can shorten the duration of the serous detachment, but it is not appropriate for juxtafoveal or subfoveal leakage point.Subvisible photocoagulation potentially localizes and decreases chorioretinal thermic burn. Subthreshold diode micropulse (SDM) laser using a 810nm diode laser may spare the damage to the neural retina by raising the temperature of the RPE to just below the protein-denaturation threshold so that the thermal wave that reaches the neural retina is insufficient to cause neither damage nor clinically visible end-point. This therapeutic laser modality offers the possibility to minimize the iatrogenic retinal lesion.

Interventions

PROCEDURESubthreshold diode micropulse laser

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Chronic active central serous chorioretinopathy lasting more than 6 months * Leakage at fluorescein angiogram

Exclusion criteria

* Opacities of the clear refractive media of the eye * Any intraocular surgery within the 6 months prior to study entry * Prior vitrectomy

Design outcomes

Primary

Measure	Time frame	Description
Best corrected visual acuity	6 months	Best corrected visual acuity measured by ETDRS chart at baseline, 1, 3, 6, 9 and 12 months

Secondary

Measure	Time frame	Description
Macular subretinal fluid	6 months	Central macular thickness measured by spectral-domain optical coherence tomography at baseline, 1, 3, 6, 9 and 12 months
Leakage at fluorescein angiogram	6 months	Leakage at fluorescein angiogram evaluated at baseline, 3, 6, 9 and 12 months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026